Nanjing Jianyou, Beijing Ted "Benzene Shun Aquku ammonium injection" will soon be approved for the market

December 17, Nanjing Jianyou, Beijing Ted according to the 4 categories of registered declaration of benzene sulfon Shun Aquku ammonium injection is in the "in the approval" stage, is expected to be approved by the State Drug Administration in the near future, the first to pass the consistent evaluation of the two enterprises.
sedative in the intensive care unit (ICU) with benzene sulfon aquco ammonium injection as an auxiliary drug for whole hemp.
it relaxes skeletal muscles, making trachea intination and mechanical airfly easy to perform.
was developed by Aspen/GSK and later acquired by GlaxoWellcome and approved by the FDA in December 1995 for a product called Nimbex ®.
was awarded the U.S. market for Glaxo Wellcome narcotic drugs in November 1999, Abbott is currently responsible for the commercial sale of the variety in the United States.
June 2004, Nimbex ® was first approved for listing in China and currently has 3 sizes of 5mg/2.5ml, 10mg/5mL, 20mg/10ml.
, Nanjing Jianyou developed a total of 3 specifications of benzene shun aquku ammonium injection, including 10 mg/5 mL, 20 mg/10 mL, 200 mg/20 mL, all approved by the FDA in April 2019.
then transferred to the domestic declaration of listing, "the same production line production, has been listed in the United States, apply for domestic listing of generic drugs" reasons were included in the priority review.
approved is the 10 mg/5 mL specification and 20 mg/10 mL is in the "in approval" phase.
that since the original 200 mg/20 mL specification has not yet been listed in China, in May 2019, NMPA concluded that clinical approval had been made.
's Benzene Shun Aquku ammonium injection (10mg/5ml, 20 mg/10 mL) was approved by the FDA for listing in the United States in September 2017 and domestically in February 2018.
because the registration time is old 6 categories.
, Henri submitted a consistent evaluation application three months after its approval and is currently in the "in review" phase.
same time, as the 200 mg/20 mL specification of the original research has not yet been listed in China, so in October 2018 Hengrui new specifications according to the 3 categories of declared listing approval conclusions are also approved clinical.
according to the medical Rubik's Cube IPM data, the national sales of benzene shun aquku ammonium injection in 2019 is about 2.175 billion yuan.
。